{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,2,10]],"date-time":"2024-02-10T00:14:44Z","timestamp":1707524084328},"reference-count":17,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,7,22]]},"DOI":"10.7759\/cureus.9347","type":"journal-article","created":{"date-parts":[[2020,7,22]],"date-time":"2020-07-22T20:28:12Z","timestamp":1595449692000},"source":"Crossref","is-referenced-by-count":2,"title":["Olmesartan-Induced Spruelike Enteropathy: An Emerging Cause of Small Bowel Injury"],"prefix":"10.7759","author":[{"given":"Adnan","family":"Malik","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Faisal","family":"Inayat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muhammad Imran","family":"Malik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muhammad","family":"Afzal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muhammad F","family":"Azrak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2012.06.003","article-title":"Severe spruelike enteropathy associated with olmesartan","volume":"87","author":"Rubio-Tapia A","year":"2012","unstructured":"Rubio-Tapia A, Herman ML, Ludvigsson JF, Kelly DG, Mangan TF, Wu TT, Murray JA. Severe spruelike enteropathy associated with olmesartan. Mayo Clin Proc. 2012, 87:732-738. 10.1016\/j.mayocp.2012.06.003","journal-title":"Mayo Clin Proc"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1093\/gastro\/goz019","article-title":"Angiotensin II receptor blockers and gastrointestinal adverse events of resembling sprue-like enteropathy: a systematic review","volume":"7","author":"Kamal A","year":"2019","unstructured":"Kamal A, Fain C, Park A, Wang P, Gonzalez-Velez E, Leffler DA, Hutfless SM. Angiotensin II receptor blockers and gastrointestinal adverse events of resembling sprue-like enteropathy: a systematic review. Gastroenterol Rep (Oxf). 2019, 7:162-167. 10.1093\/gastro\/goz019","journal-title":"Gastroenterol Rep (Oxf)"},{"key":"ref3","unstructured":"FDA Drug Safety Communication. FDA approves label changes to include intestinal problems (sprue-like enteropathy) linked to blood pressure medicine olmesartan medoxomil. (2013). Accessed: February 21, 2020: https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-drug-safety-communication-fda-approves-label-changes-inclu...."},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v19.i40.6928","article-title":"Angiotensin-II inhibitor (olmesartan)-induced collagenous sprue with resolution following discontinuation of drug","volume":"19","author":"Nielsen JA","year":"2013","unstructured":"Nielsen JA, Steephen A, Lewin M. Angiotensin-II inhibitor (olmesartan)-induced collagenous sprue with resolution following discontinuation of drug. World J Gastroenterol. 2013, 19:6928-6930. 10.3748\/wjg.v19.i40.6928","journal-title":"World J Gastroenterol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.12691\/ijcd-2-2-5","article-title":"Drug-induced Sprue-like intestinal disease","volume":"2","author":"Freeman HJ","year":"2014","unstructured":"Freeman HJ. Drug-induced Sprue-like intestinal disease. Int J Celiac Dis. 2014, 2:49-53. 10.12691\/ijcd-2-2-5","journal-title":"Int J Celiac Dis"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1111\/apt.14518","article-title":"Use of olmesartan and enteropathy outcomes: a multi-database study","volume":"47","author":"Dong YH","year":"2018","unstructured":"Dong YH, Jin Y, Tsacogianis TN, He M, Hsieh PH, Gagne JJ. Use of olmesartan and enteropathy outcomes: a multi-database study. Aliment Pharmacol Ther. 2018, 47:792-800. 10.1111\/apt.14518","journal-title":"Aliment Pharmacol Ther"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200868090-00005","article-title":"Olmesartan medoxomil: a review of its use in the management of hypertension","volume":"68","author":"Scott LJ","year":"2008","unstructured":"Scott LJ, McCormack PL. Olmesartan medoxomil: a review of its use in the management of hypertension. Drugs. 2008, 68:1239-1272. 10.2165\/00003495-200868090-00005","journal-title":"Drugs"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1111\/apt.12780","article-title":"Systematic review: sprue-like enteropathy associated with olmesartan","volume":"40","author":"Ianiro G","year":"2014","unstructured":"Ianiro G, Bibb\u00f2 S, Montalto M, Ricci R, Gasbarrini A, Cammarota G. Systematic review: sprue-like enteropathy associated with olmesartan. Aliment Pharmacol Ther. 2014, 40:16-23. 10.1111\/apt.12780","journal-title":"Aliment Pharmacol Ther"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.5858\/arpa.2015-0204-RA","article-title":"Olmesartan-associated enteropathy: a review of clinical and histologic findings","volume":"139","author":"Choi EY","year":"2015","unstructured":"Choi EY, McKenna BJ. Olmesartan-associated enteropathy: a review of clinical and histologic findings. Arch Pathol Lab Med. 2015, 139:1242-1247. 10.5858\/arpa.2015-0204-RA","journal-title":"Arch Pathol Lab Med"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.dld.2013.12.014","article-title":"Five cases of sprue-like enteropathy in patients treated by olmesartan","volume":"46","author":"Th\u00e9ophile H","year":"2014","unstructured":"Th\u00e9ophile H, David XR, Miremont-Salam\u00e9 G, Haramburu F. Five cases of sprue-like enteropathy in patients treated by olmesartan. Dig Liver Dis. 2014, 46:465-469. 10.1016\/j.dld.2013.12.014","journal-title":"Dig Liver Dis"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/494098","article-title":"Olmesartan associated sprue-like enteropathy and colon perforation","volume":"2014","author":"Abdelghany M","year":"2014","unstructured":"Abdelghany M, Gonzalez L, Slater J, Begley C. Olmesartan associated sprue-like enteropathy and colon perforation. Case Rep Gastrointest Med. 2014, 2014:3. 10.1155\/2014\/494098","journal-title":"Case Rep Gastrointest Med"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.humpath.2015.12.001","article-title":"Olmesartan-associated sprue-like enteropathy: a systematic review with emphasis on histopathology","volume":"50","author":"Burbure N","year":"2016","unstructured":"Burbure N, Lebwohl B, Arguelles-Grande C, Green PH, Bhagat G, Lagana S. Olmesartan-associated sprue-like enteropathy: a systematic review with emphasis on histopathology. Hum Pathol. 2016, 50:127-134. 10.1016\/j.humpath.2015.12.001","journal-title":"Hum Pathol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1111\/apt.12937","article-title":"Olmesartan-associated enteropathy: results of a national survey","volume":"40","author":"Marthey L","year":"2014","unstructured":"Marthey L, Cadiot G, Seksik P, et al.. Olmesartan-associated enteropathy: results of a national survey. Aliment Pharmacol Ther. 2014, 40:1103-1109. 10.1111\/apt.12937","journal-title":"Aliment Pharmacol Ther"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpge.2015.09.005","article-title":"Olmesartan-induced enteropathy: an unusual cause of villous atrophy","volume":"23","author":"Eus\u00e9bio M","year":"2016","unstructured":"Eus\u00e9bio M, Caldeira P, Antunes AG, Ramos A, Velasco F, Cadill\u00e1 J, Guerreiro H. Olmesartan-induced enteropathy: an unusual cause of villous atrophy. GE Port J Gastroenterol. 2016, 23:91-95. 10.1016\/j.jpge.2015.09.005","journal-title":"GE Port J Gastroenterol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.12659\/AJCR.913207","article-title":"Olmesartan associated enteropathy: a rare underdiagnosed cause of diarrhea and weight loss","volume":"20","author":"Gonakoti S","year":"2019","unstructured":"Gonakoti S, Khullar S, Rajkumar A. Olmesartan associated enteropathy: a rare underdiagnosed cause of diarrhea and weight loss. Am J Case Rep. 2019, 20:111-116. 10.12659\/AJCR.913207","journal-title":"Am J Case Rep"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.12890\/2019_001093","article-title":"Olmesartan-associated enteropathy: an unexpected cause of chronic diarrhoea","volume":"6","author":"Teixeira M","year":"2019","unstructured":"Teixeira M, Macedo S, Martins A, Batista T, Novais A, Costa M, Cancela E. Olmesartan-associated enteropathy: an unexpected cause of chronic diarrhoea. Eur J Case Rep Intern Med. 2019, 6:001093. 10.12890\/2019_001093","journal-title":"Eur J Case Rep Intern Med"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpge.2016.02.005","article-title":"Sprue-like enteropathy associated with olmesartan: a new kid on the enteropathy block","volume":"23","author":"Hujoel IA","year":"2016","unstructured":"Hujoel IA, Rubio-Tapia A. Sprue-like enteropathy associated with olmesartan: a new kid on the enteropathy block. GE Port J Gastroenterol. 2016, 23:61-65. 10.1016\/j.jpge.2016.02.005","journal-title":"GE Port J Gastroenterol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/28459-olmesartan-induced-spruelike-enteropathy-an-emerging-cause-of-small-bowel-injury","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:20:21Z","timestamp":1707506421000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/28459-olmesartan-induced-spruelike-enteropathy-an-emerging-cause-of-small-bowel-injury"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,22]]},"references-count":17,"URL":"https:\/\/doi.org\/10.7759\/cureus.9347","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2020,7,22]]}}}